Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment

April 28, 2014

A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings support efforts to reduce the side effects and burden of treatments for breast cancer and to identify patients who may forego certain treatments, particularly when the expected benefit is low.

Many women with early-stage are working at the time of diagnosis and survive without cancer recurrence. Therefore, it's important to understand the impacts of on early-stage ' employment. Reshma Jagsi, MD, of the University of Michigan Health System, and her colleagues studied 2290 women in the Los Angeles and Detroit areas who were diagnosed with nonmetastatic breast cancer between 2005 and 2007 and who completed surveys soon after diagnosis; 1536 of the women also completed a four-year follow-up questionnaire.

Of the 1026 patients under age 65 at diagnosis whose breast cancer did not recur and who responded to both surveys, 746 (76 percent) worked for pay before diagnosis. Of these, 236 (30 percent) were no longer working at follow-up. Women who received chemotherapy as part of initial treatment were less likely to be working at the four-year follow-up than women who were not treated with chemotherapy (38 percent vs 27 percent). Calculations showed that women who received chemotherapy at the time of were 1.4-times more likely to be subsequently unemployed. Many who were not employed after treatment wanted to work: 50 percent reported that it was important for them to work and 31 percent were actively seeking work.

"Many clinicians believe that although patients may miss work during treatment, they will 'bounce back' in the longer term. The results of this study suggest otherwise and highlight a possible long-term adverse consequence to adjuvant chemotherapy that may not have been fully appreciated to date," said Dr. Jagsi. She stressed the need to continue to develop strategies to identify patients who receive little benefit from chemotherapy and might be able to avoid it. "We also need to ensure that who are deciding on whether to receive chemotherapy understand the potential long-term consequences of receiving treatment, including possible implications for their employment and financial outcomes," she said.

Explore further: Twenty-five percent of breast cancer survivors report financial decline due to treatment

More information: "Impact of adjuvant chemotherapy on long-term employment of early-stage breast cancer survivors." Reshma Jagsi, Sarah T. Hawley, Paul Abrahamse, Yun Li, Nancy K. Janz, Jennifer J. Griggs, Cathy Bradley, John J. Graff, Ann S. Hamilton, and Steven J. Katz. Cancer; Published Online: April 28, 2014 DOI: 10.1002/cncr.28607

Related Stories

Twenty-five percent of breast cancer survivors report financial decline due to treatment

March 25, 2014
Four years after being treated for breast cancer, a quarter of survivors say they are worse off financially, at least partly because of their treatment, according to a new study led by University of Michigan Comprehensive ...

Breast cancer patients in need of more psychological support

March 20, 2014
For women who are suffering from breast cancer, concern for their children is the greatest source of worry. A researcher at The University of Gothenburg, Sweden, has shown this, and believes that women who are at the earliest ...

Most breast cancer patients return to working same hours

July 12, 2012
(HealthDay) -- Nearly three-quarters of women treated for breast cancer return to their prediagnosis working time, according to a study published online July 9 in the Journal of Clinical Oncology.

Additional drug shows promise for women with triple-negative breast cancer

December 13, 2013
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...

Fertility concerns common for young women with breast CA

February 27, 2014
(HealthDay)—Fertility concerns are common among young women with newly diagnosed breast cancer, although only a minority pursue fertility preservation strategies, according to a study published online Feb. 24 in the Journal ...

Early breast cancer diagnosis, survival rates low in rural India

February 4, 2013
Women in developed countries survive roughly 10 years longer after a breast cancer diagnosis compared to women in poor-to-middle-income countries, a new University of Michigan study suggests.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.